A record of what Marketsmith India Analysis said publicly, with the source. Not advice.
“Recommends buying Biocon Ltd between ₹380-395, targeting ₹454 in two to three months with a stop loss at ₹368. The call is driven by stable biosimilar performance, strong growth from its Syngene subsidiary, robust R&D, and a cup-with-handle pivot breakout, with the stock trending above key moving averages.”
Marketsmith India Analysis’s track record (trackable calls only): 322 graded calls · 95% CI 22–32%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
Entry zone: ₹380–₹395. The call starts at the first close that comes into it.
Target ₹454, stop ₹368, as stated.
Window: 90 days, the time frame the call states ("two to three months").
The stop ₹368 was reached on a close before the target ₹454. Miss.
The grader’s working: R3 TRADE_SETUP: entered ₹391.4 on 2025-07-31 (stated entry ₹380–395 zone, ZONE entry, filled); stop ₹368 breached at close ₹360.4 on 2025-08-06. Window 90 days — rule H1: the quote states "two to three months".
How it played out
How this is worked out- Target or stop first
- The stop was reached on a close before the target was.
- Time to target
- The target was not reached on a close inside the window.
- Worst close against it
- The closing price went as far as 7.92% against the call up to 6 Aug 2025, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.